septerna - Search News

News

Novo Nordisk Inks A Major Obesity Deal

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

UPI on MSN · 1d

Novo Nordisk, U.S. biotech company team up to create obesity pills

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Reuters on MSN · 3d

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

PMLive1d

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

STAT3d

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Novo Nordisk Inks A Major Obesity Deal

Related topics